Enterix !nsure
This article was originally published in The Gray Sheet
Executive Summary
Immunoassay fecal-occult blood test kit has been referred to the Agency for Healthcare Research & Quality for a technology assessment that will include cost-effectiveness analysis, CMS announces March 3. Medicare began the national coverage determination process for the colorectal cancer assay March 1 (1"The Gray Sheet" Jan. 27, 2003, p. 16)...